Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2006;98:887-896
doi: 10.1161/01.RES.0000217340.40936.53
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleming, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleming, I.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Cell signalling/signal transduction
(Circulation Research. 2006;98:887.)
© 2006 American Heart Association, Inc.


Reviews

Signaling by the Angiotensin-Converting Enzyme

Ingrid Fleming

From the Vascular Signalling Group, Institut für Kardiovaskuläre Physiologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany.

Correspondence to Ingrid Fleming, PhD, Vascular Signalling Group, Institut für Kardiovaskuläre Physiologie, Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany. E-mail fleming{at}em.uni-frankfurt.de

This Review is part of a thematic series on Angiotensin-Converting Enzyme, which includes the following articles:

Six Truisms Concerning ACE and the Renin-Angiotensin System Educed from the Genetic Analysis of Mice

ACE II in the Heart and the Kidney

Signaling by the Angiotensin-Converting Enzyme

ACE Polymorphisms

ACE and Vascular Remodeling
Rudi Busse Editors

Inhibition of the angiotensin-converting enzyme (ACE) protects against the progression of several cardiovascular diseases. Because of its dual role in regulating angiotensin II and bradykinin levels, the positive clinical effects of ACE inhibitors were thought to be the consequence of concomitant reductions in the production of angiotensin II and the degradation of bradykinin. Recent evidence suggests that some of the beneficial effects of ACE inhibitors on cardiovascular function and homeostasis can be attributed to novel mechanisms. These include the accumulation of the ACE substrate N-acetyl-seryl-aspartyl-lysyl-proline, which blocks collagen deposition in the injured heart, as well as the activation of an ACE signaling cascade that involves the activation of the kinase CK2 and the c-Jun N-terminal kinase in endothelial cells and leads to changes in gene expression. Moreover, at least one other ACE homologue (ACE2) is proposed to counteract the detrimental effects associated with the activation of the classical renin-angiotensin system. These data reveal hitherto unexpected levels of internal regulation of the renin-angiotensin system.


Key Words: ACEangiotensin II • basic science • c-Jun NH2-terminal kinase • macrophages • signal transduction




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
K. Kohlstedt, C. Gershome, C. Trouvain, W.-K. Hofmann, S. Fichtlscherer, and I. Fleming
Angiotensin-Converting Enzyme (ACE) Inhibitors Modulate Cellular Retinol-Binding Protein 1 and Adiponectin Expression in Adipocytes via the ACE-Dependent Signaling Cascade
Mol. Pharmacol., March 1, 2009; 75(3): 685 - 692.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Simard, D. Jin, S. Takai, M. Miyazaki, I. Brochu, and P. D'Orleans-Juste
Chymase-Dependent Conversion of Big Endothelin-1 in the Mouse in Vivo
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 540 - 548.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
V. Koka, X. R. Huang, A. C.K. Chung, W. Wang, L. D. Truong, and H. Y. Lan
Angiotensin II Up-Regulates Angiotensin I-Converting Enzyme (ACE), but Down-Regulates ACE2 via the AT1-ERK/p38 MAP Kinase Pathway
Am. J. Pathol., May 1, 2008; 172(5): 1174 - 1183.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. A. Sabatini, P. B. Guimaraes, L. Fernandes, F. C.G. Reis, P. A. Bersanetti, M. A. Mori, A. Navarro, A. M. Hilzendeger, E. L. Santos, M. C.C. Andrade, et al.
ACE Activity Is Modulated by Kinin B2 Receptor
Hypertension, March 1, 2008; 51(3): 689 - 695.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
R. M. Wosten-van Asperen, R. Lutter, J. J. Haitsma, M. P. Merkus, J. B. van Woensel, C. M. van der Loos, S. Florquin, B. Lachmann, and A. P. Bos
ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin
Eur. Respir. J., February 1, 2008; 31(2): 363 - 371.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. P. De Bono and K. M. Channon
Endothelial Cell Tetrahydrobiopterin: Going With the Flow
Circ. Res., October 12, 2007; 101(8): 752 - 754.
[Full Text] [PDF]


Home page
Circ. Res.Home page
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen
Angiotensin-Converting Enzyme and Vascular Remodeling
Circ. Res., August 31, 2007; 101(5): 441 - 454.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. S. Kasi, H. D. Xiao, L. L. Shang, S. Iravanian, J. Langberg, E. A. Witham, Z. Jiao, C. J. Gallego, K. E. Bernstein, and S. C. Dudley Jr.
Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H182 - H192.
[Abstract] [Full Text] [PDF]